Object. The Wilms tumor 1 (WT1) protein-a developmentally regulated transcription factor-is aberrantly expressed in gliomas and promotes their malignant phenotype. However, little is known about the molecular allies that help it mediate its oncogenic functions in glioma cells.
T he WT1 protein was originally believed to function as a tumor suppressor. Early studies showed that the protein repressed the transcription of several oncogenic proteins, such as PDGF-A, transforming growth factor-b, EGF receptor, and insulin-like growth factor-I receptor, and increased the expression of genes that prevented malignant transformation, such as E-cadherin, and proapoptotic proteins (reviewed by Yang et al. 46 ). However, subsequent studies showed that the ability of WT1 to transcriptionally activate or repress a putative target depended largely on which cell type was being used, the isoforms studied, the number of WT1 binding sites present on the target promoter, and other factors (reviewed by Yang et al. 46 ). Moreover, the escalating incidence of its discovery in malignant cells from several different tissue types (reviewed by Sugiyama 37 ) implicated WT1 in oncogenesis. A key regulator of various developmental processes, WT1 expression was known to be switched off as tissues developed into the normal adult stage. 15, 16, 19, 35 However, wildtype WT1 was found to be expressed in leukemias and other hematopoietic malignancies, lung and breast cancers, gastrointestinal cancers, sarcomas, tumors in the head and neck, reproductive organ neoplasms, and gliomas (reviewed by Sugiyama 37 ) . In most or all of these tumors, WT1 expression appeared to play a decisive role in promoting proliferation, invasion, and/or angiogenesis. 3, 6, 7, 10, 11, 18, 22, [24] [25] [26] [27] [28] [29] [30] [31] 34, 36, 38, 39, 42 We have previously demonstrated WT1 expression in approximately 80% of glioma cell lines and tumor speci-Novel report of expression and function of CD97 in malignant gliomas: correlation with Wilms tumor 1 expression and glioma cell invasiveness mens. 5 The predominant WT1 isoform expressed in these cells contained a 17-amino acid peptide coded for by exon 5 and the tripeptide KTS between zinc fingers 3 and 4 (WT1 +/+). Our studies showed that glioma cells that had endogenous WT1 expression relied heavily on this protein for their growth and motility. 3, 6 WT1 also conferred upon these cells resistance to radiation therapy and some chemotherapeutic agents. 3, 4 In the current study, we examined 2 additional GBM cell lines-U1242-MG and GBM-6-for the expression and function of WT1. Previous studies have shown that these 2 cell lines are highly invasive and mimic the pathology of GBM when implanted orthotopically in athymic mice. 12, 49 Endogenous expression of WT1 was noted in both these cell lines. We also observed that WT1 profoundly influenced cellular invasiveness in these cell lines.
The question that arose from these observations then was: how was WT1 mediating these effects in glial neoplasms?
Given its structural identity-a zinc finger transcription factor-and its functional history, it seemed logical that WT1 might regulate the transcription (or posttranscriptional expression) of other genes that might then directly cause the above-mentioned effects. Therefore, to identify which genes might vary in glioma cells in their expression patterns as a result of WT1-mediated regulation, we used gene microarray analysis to characterize differential gene expression. This method permits rapid screening of thousands of genes to find the possible candidate genes that are differentially expressed as a result of any manipulations. Our analyses revealed the identity of some such presumed or established oncogenes whose levels paralleled that of WT1 in glioma cells-PDGF-D, TYMS, INPP5A, CD97, and FAM57A. Genes whose expression levels were increased as a result of WT1 suppression, on the other hand, included putative tumor suppressors, such as LZTS1, TIMP3, MAFF, and WIPI1. We then sought to ascertain if there was any correlation between the expression levels of WT1 and these candidate target genes in the U1242-MG and GBM-6 cells.
Our experiments showed that CD97 was significantly downregulated in all 3 cell lines investigated-U251-MG, U1242-MG, and GBM-6. We selected CD97 for further investigation, based on its consistent and direct correlation with WT1 across the GBM cell lines examined and because of its putative roles in facilitating cell invasiveness and neoangiogenesis in gastrointestinal and thyroid tumors. 1, 14, 21, 41, 43 This is the first time that expression of this oncogene has been reported in neoplastic glial cells.
CD97 is a cell surface receptor that belongs to the adhesion G-protein-coupled receptor (GPCR) family. It is therefore characterized by heptahelical hydrophobic segments that form the 7 transmembrane domains, an extracellular N terminus containing EGF-like structural domains (comprising the a-subunit), and an intracellular C terminus. 47 Through alternative splicing of the mRNA transcript, 3 isoforms of the a-subunit of CD97 can be generated that differ in the number of EGF repeats they contain; these isoforms are hCD97 (EGF 1, 2, 5), hCD97 (EGF 1, 2, 3, 5), and hCD97 (EGF 1, 2, 3, 4, 5). 13 Also present in the amino-acid sequence of the extracellular segment, after the EGF-like repeats and before the first membrane-spanning sequence at position 318, is an RGD motif. This motif acts as a binding site for several classes of integrins, which are known to mediate attachment to the extracellular matrix and to other cells. 13 The ligands that have been found to bind CD97 include CD55/decay accelerating factor (DAF) (involved in protection from complement-mediated attack and lysis), chondroitin sulfate (a glycosaminoglycan that affects cell attachment), and a 5 b 1 integrin. 41 Interestingly, the intracellular signaling mechanism(s) by which CD97 and other adhesion-GPCR family members might act is (are) yet unclear. 20 Expression of CD97 has been reported mainly in leukocytes, and in this group, it has been found predominantly in myeloid cells. CD97 expression has also been reported in smooth muscle cells and in epithelial tumors. 41 Its expression in thyroid carcinoma cells has been linked with promoting de-differentiation, 1 while in colorectal and gastric carcinomas and fibrosarcomas, its expression has been associated with cellular invasiveness. 20 Our results corroborated the findings from these earlier studies and we confirm that in glioma cells, also, CD97 appears to influence cellular invasiveness. Future studies will seek to confirm whether WT1 regulates expression of this protein at the transcriptional and/or posttranscriptional level(s).
Methods

Cell Culture
Cells from the human glioma cell line U251-MG were obtained from ATCC; U1242-MG cells were a kind gift from Dr. James Van Brocklyn (Ohio State University), and GBM-6 cells were generously provided by Dr. C. David James (University of California, San Francisco) via Dr. Paul Dent (VCU). All cells were cultured in DMEM containing 10% fetal bovine serum, glutamine, nonessential amino acids, and 1% penicillin-streptomycin in a humidified atmosphere of 5% CO 2 . Normal human astrocyte RNA (catalog #1805) was procured from ScienCell Research Laboratories.
Short Interfering RNA Transfections
Cells were plated in 6-well plates at a density of 1.5-2 × 10 5 cells per well. Twenty-four hours after plating, the cells were transfected as described previously. 4 Cells were divided into the following groups: those that had only Oligofectamine (Invitrogen) added to them (ctrl), those that were treated with nontargeting siRNA control (scr), and those that had been treated with siRNA targeting WT1 or CD97 (si). The final concentration of nontargeting siRNA control, anti-WT1 siRNA, and anti-CD97 siRNA was 100 nM, a concentration that was determined by performing optimization experiments. Twenty-four hours after transfection, 10% DMEM supplemented with 1% penicillinstreptomycin was added. Forty-eight hours after transfection, the cells were harvested with trypsin, and following resuspension of the cell pellet in 10% DMEM, the cells were replated for RNA extraction for qRT-PCR and microarray analyses, protein extraction for Western blotting, and cell proliferation and/or invasion assays.
RNA Extraction
RNA was extracted using Trizol (Invitrogen) according to the manufacturer's protocol. Following RNA extraction, the RNA content was quantified using a spectrophotometer, and approximately 12 mg of RNA per sample was subjected to DNase treatment using RQ1 DNase (Promega). Samples were then analyzed using qRT-PCR. Synthesis of probes and primers for anti-WT1 siRNA was carried out at the VCU Nucleic Acid Research Facilities. The Taqman primer mixes for the target genes were purchased from Applied Biosystems. All qRT-PCR reactions were performed at the VCU Nucleic Acid Research Facilities.
Western Blotting
Protein was extracted from cell lines using SDS buffer (50 mM Tris-C1, 1% SDS, 10% glycerol) supplemented with protease inhibitors. The concentration of protein was determined by DC protein assay (Bio-Rad). For protein analysis of cells transfected with anti-WT1 siRNA, 10 mg of total protein lysate was separated by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membrane according to the manufacturer's protocol (Invitrogen). The membrane was then blocked with 5% nonfat milk solution for 1 hour at room temperature. Mouse anti-WT1 monoclonal antibody (1:200 dilution, clone: 6F-H2, Dako) and rabbit anti-CD97 polyclonal antibody (1:200, Abcam) were diluted in blocking buffer, and the blots were incubated with the respective primary antibodies overnight at 4°C. After this, the membranes were washed 6 times in Tris-buffered saline containing 0.05% Tween-20 before and after a 1-hour incubation at room temperature with horseradish peroxidase-conjugated anti-mouse (1:2000) and anti-rabbit (1:3000) secondary antibodies directed against anti-WT1 and anti-CD97, respectively. Anticyclophilin A monoclonal antibody (1:30,000, Upstate Biotechnology) was used as a control for protein loading. Blots were developed using Pierce SuperSignal West Dura Substrate.
Cell Proliferation Assay
Cellular proliferation was measured at specified time points after transfection using the CellTiter-Glo luminescent cell viability assay (Promega). The cells that were plated in opaque 96-well plates 48 hours after transfection were lysed for 15 minutes in CellTiter-Glo ATP viability assay reagents as per the protocol. Relative luminescence was then detected on a LUMIstar luminescence plate reader (BMG Labtech).
Invasion Assay
Matrigel (BD Biosciences), previously aliquoted, was thawed at 4°C on ice overnight before use. Forty-eight hours posttransfection, cells were plated on Matrigelcoated 8.0-mm pore polycarbonate membrane inserts of 6.5-mm Transwell plates (Corning) at a density of 5000 cells/500 ml. Ninety-six hours following transfection, the medium was removed from the filters and the lower chambers, the upper part of each filter was scraped with cotton-tipped applicators to remove the cells that had not invaded, and each lower chamber was rinsed with phos-phate-buffered saline. Then 200 ml of 1× trypsin-EDTA (prepared by diluting in phosphate-buffered saline a 10× solution of 0.5% trypsin-EDTA containing 5 mg/ml of trypsin with 4.81 mM Na-EDTA in 146.55 mM sodium chloride) was added to each chamber to harvest the cells, and after a 5-minute incubation at 37°C, 800 ml of 10% DMEM was used to neutralize the enzyme. The lower part of each filter was rinsed with medium to collect cells that had invaded through the Matrigel-coated insert but had not adhered to the base of the lower chamber. After centrifugation at 1000 rpm for 5 minutes to collect the cells, the supernatant was removed from each tube, and fresh medium was added to a volume of 500 ml. The entire volume was then plated (100 ml/well) into an opaque 96-well plate for assaying the ATP content as described above.
Gene Expression Profiling
The microarray reactions were performed using the Affymetrix GeneChip standard protocol as previously described. 9 Quality analyses of all RNA samples, as well as cDNA and cRNA synthesis products, were carried out before proceeding further by running 1 ml of every sample in RNA 6000 Nano or DNA 7500 LabChips on the 2100 Bioanalyzer (Agilent), following the manufacturer's protocol. Quality control criteria included cDNA and cRNA synthesis products within median lengths of 2.0 and 3.0 kb, respectively, and 3ʹ/5ʹ ratios close to 1.00 for the housekeeping genes, GAPDH and β-actin. 8 The "significance-score" algorithm (S-score) developed by Dr. Li Zhang was used to produce a score for the comparisons of the expression summaries between cell groups. 48 The Minimum Information About a Microarray Experiment guidelines have been met, and the microarray raw data have been deposited with the National Center for Biotechnology Institute Gene Expression Omnibus-accession number GSE22578.
Statistical Analysis
All comparisons were between 2 cell groups: 1) cells treated with nontargeting siRNA or untreated cells; and 2) cells treated with siRNA directed against WT1 or CD97. Each experiment was replicated at least 3 times, and results are presented as mean values with SDs. The Student t-test (2-tailed, paired) was used, and a calculated p value of ≤ 0.05 was considered statistically significant.
Results
Expression and Function of WT1 in U1242-MG and GBM-6 Cells
Using Western blotting, we detected WT1 expression in U1242-MG and GBM-6 cell lines ( Fig. 1A) . Cell extracts from the prostatic carcinoma cell line (PC3) were used as a positive control for WT1. Both GBM-6 and U1242-MG show the characteristic WT1 double band, suggesting the possibility of the + andexon 5 variants that differ by 17 amino acids, at the predicted molecular weight level (52-54 kDa).
After using siRNA directed against WT1, we confirmed efficient silencing of this transcription factor by qRT-PCR ( Fig. 1B) . On the 3rd day after transfection, we found that the level of WT1 mRNA in GBM-6 cells treated with anti-WT1 siRNA was 14.44% (± 2.89%) of that seen in their control counterparts that had been treated with nontargeting siRNA (p ≤ 0.001). In U1242-MG cells, there was less knockdown (50.47% [± 3.49%] of control levels), which was nevertheless highly significant (p ≤ 0.001).
We observed that these decreases in cellular content of WT1 remarkably depressed the invasive capacity of these cells (Fig. 1C ). In GBM-6 cells, there was nearly a 95% decrease (± 22.65%) in the ability of the anti-WT1 siRNA-treated cells to invade through the Matrigel-coated filter (p ≤ 0.05) compared with the control cells, while in U1242-MG cells, silencing of WT1 caused a decrease in cellular invasiveness to 20.62% (± 1.12%) of the control cells (p ≤ 0.001). These differences in the ability to invade could potentially be accounted for by decreased proliferative rates in the siRNA-transfected cells versus control cells. Hence, we performed cell viability assays on these same groups of cells. Our results showed that the growth rates of control and siRNA-treated cells were not significantly different across 3 independent experiments (data not shown). Also, based on our previous experiments we found no statistically significant differences between untreated cells and cells treated with nontargeting siRNA (scr). Hence, we show only comparisons between groups treated with nontargeting and targeting siRNA.
Gene Expression Profiling: Putative Target Genes for WT1 in U251-MG Glioma Cells
To ascertain the identity of the potential target genes for WT1 in the particular context of glioma cells, we chose to perform gene expression profiling experiments. On 3 separate occasions, U251-MG cells were treated with Oligofectamine alone (ctrl), nontargeting RNA (scr), or siRNA against WT1. After confirming WT1 knockdown with qRT-PCR in the siRNA-treated samples each time, microarray analyses were carried out using the Affymetrix GeneChip Standard protocol. Quality control checks were performed, and RNA samples that met the criteria described in detail in our previous studies 40 were used for microarray analyses. The S-score analyses of the data obtained in the 3 sets of experiments are summarized in Tables 1 and 2 , revealing a total of 27 genes that were downregulated and 11 genes that were upregulated, respectively, in response to WT1 silencing. These genes passed 2 separate levels of stringency for being declared significantly altered-the S-score, which establishes sig nificance at the univariate level, and the Benjamini-Hoch berg correction, which corrects for multiple comparisons. 38 The fold change of each gene in these tables is expressed as the mean value of the results for that gene from the 3 different microarray experiments. For clarity, standard deviations for these values are not shown, but they represented up to 30% of the mean values. Super- Cell invasiveness in WT1-silenced cells was assessed by using the CellTiter-Glo assay (RLU is a surrogate for cell number) to first quantify the number of cells that had invaded through the Matrigel in the si groups versus the scr groups and then expressing this value as a percentage of that seen in control (scr) cells. All experiments were performed in triplicate with separate cultured samples of tumor cells treated in parallel with siRNA against WT1 and corresponding controls.
vised cluster analyses from 3 independent experiments based on these 38 genes showed that the "ctrl" and "scr" cell groups cluster together and separately from the "si" group of cells that were treated with siRNA ( Fig. 2) . Thus, Fig. 2 represents an experiment performed in triplicate over the course of multiple weeks, with separate cultured samples of U251-MG cells treated in parallel for knockdown of WT1 expression with corresponding controls. To the left side of the heat map is a list of all the genes whose levels were found to be altered with this manipulation. WT1 (highlighted in yellow) appears prominently downregulated as a result of our experimental treatment, confirming the successful downregulation using siRNA knockdown. Also, there is a high level of consistency in the patterns of up-or downregulation of the selected genes, among the corresponding replicates (ctrl, scr-, or si-treated) from the 3 experiments performed.
Among the genes that were downregulated with WT1 silencing, implying a direct correlation, several (identified by searching the available literature) had either putative or established oncogenic roles in gliomas and/or other malignancies. These genes included ICK, INPP5A, TYMS, PDGF-D, CD97, EPAS1, FAM57A, KRT18, and HSPC111 (Table 1) . Conversely, the genes that inversely correlated with WT1 levels included some prominent tumor suppressors such as SSAT1, LZTS1, WIPI1, TIMP3, SOX11, MAFF, and DPYSL3.
Validation of Microarray Findings Using qRT-PCR
We used qRT-PCR to validate our microarray findings, because it was quicker and more sensitive and would provide information pertaining to the gene expression lev- els, which was of particular interest to us since we were assessing the potential transcriptional targets of WT1. For our validation experiments, we selected from among all the targets identified by microarray only those that had been implicated as having a relevant role in oncogenesis or tumor suppression based on literature search. As with the microarray studies, siRNA-transfection, scr-transfection, and control (Oligofectamine alone) treated cells were prepared on 3 separate occasions, and RNA extracts were then subjected to qRT-PCR as described in Methods for the putative target genes. Furthermore, certain genes such as ICK, KRT18, and TIMP3 are not represented in the graph owing to lack of reproducible results. The 2 -DDCT method was used to calculate fold changes in the mRNA expression levels of the candidate genes against b-actin mRNA. The values thus obtained for the si groups of cells were then compared with the corresponding values in the scr groups of cells. Figure 3 represents a comparison of the fold change of each candidate gene obtained from the qRT-PCR analyses (bar graph) against the corresponding value derived from the microarray analyses (line graph). We successfully substantiated the microarray results with qRT-PCR by showing that, with both sets of genes, there is a consistent trend toward down-or upregulation of their expression levels. In the case of the genes that were downregulated with WT1 silencing, the magnitude of the foldchange values identified by means of qRT-PCR (range 0.25 ± 0.04 to 0.53 ± 0.22) was seen to be close to or only slightly different from that of the fold-change values obtained through the microarray experiments (0.16-0.35).
With the inversely correlated genes, the fold-change values were much higher in the microarray results (2.6-to 3.7-fold differences) than in the qRT-PCR results (range 0.9 ± 0.21 to 1.9 ± 1.07).
Confirmation of Putative Target Genes in U1242-MG and GBM-6 Cell Lines
We subsequently investigated whether these genes that were dysregulated in U251-MG cells were similarly altered by WT1 silencing in U1242-MG and GBM-6 cells. Both of these cell lines were subjected to siRNA transfections targeting WT1, and nontargeting siRNA (scr) was used to generate appropriate controls. Again, for each cell line, results were generated from 3 independent experiments. Using qRT-PCR, we found that from among the genes whose expression levels paralleled those of WT1, INPP5A, CD97, and TYMS were downregulated in the si groups in both U1242-MG and GBM-6 cells compared with scr groups (Fig. 4) . In GBM-6 cells, the extent of knockdown of these genes was as follows: INPP5A-51.77% ± 0.26% (p ≤ 0.05); CD97-49.6% ± 0.14% (p ≤ 0.01); and TYMS-52.4% ± 0.16%, (p ≤ 0.01). Additionally, in GBM-6 cells, the expression levels of PDGF-D and FAM57A in the siRNA-treated groups of cells were significantly decreased to 16 .2% (± 0.06%; p ≤ 0.01) and 44.1% (± 0.23%; p ≤ 0.05) of their scr counterparts, respectively. In U1242-MG cells, the extent of knockdown of these candidate target genes (as a percentage of scr control) was as follows: INPP5A-65.5% ± 0.11% (p ≤ 0.01); CD97-30.6% ± 0.09% (p ≤ 0.05); and TYMS-47.7% ± 0.04% (p ≤ 0.01). Additionally, in U1242-MG cells the expression of EPAS1, a potent angiogenesis facilitator, was also decreased with WT1 silencing. The siRNA-treated U1242-MG cells had 77.5% of EPAS1 expression compared with their corresponding control values, although statistical significance could not be established. For the genes that microarray analyses demonstrated to be upregulated with WT1 silencing (that is, inversely correlated with WT1 expression), we found a trend toward an increase in DPYSL and MAFF (GBM-6) and WIPI1 (U1242-MG), but the high variability across the 3 independent experiments precluded the establishment of statistical significance.
Analysis of Expression and Function of CD97 in GBM Cells
Based on our microarray findings and our confirmatory findings using qRT-PCR, we conducted promoter analyses to look for potential binding sites in the promoter regions of the genes that appeared to be differentially regulated by WT1 (data not shown). With the exception of PDGF-D (which had binding sites for Egr-1, but not specifically WT1), all the remaining candidate target genes were found to have at least 1 potential WT1 binding site in their promoter regions. This information, coupled with the consistent CD97 downregulation in all 3 GBM cell lines that had been treated with anti-WT1 siRNA, led us to further examine the role of CD97 in these cells with respect to its expression levels and consequent effects on cellular invasiveness.
We first determined the expression of CD97 at the protein level using Western blot analysis, which revealed that it was expressed in all 3 cell lines examined (Fig.  5A) . We then compared the mRNA expression levels of CD97 in normal human astrocytes to those in the GBM cell lines-U251-MG, U1242-MG, and GBM-6-and found 6-to 21-fold greater CD97 mRNA levels in the 3 cell lines than in normal human astrocytes (Fig. 5B) .
Subsequently, CD97 expression in all 3 glioma cell lines was downregulated by siRNA transfection methods, and the biological effects of this manipulation were examined. As shown in Fig. 5C , qRT-PCR analyses demonstrated a significant knockdown in all 3 cell lines even at Day 4 posttransfection (p < 0.05). In U251-MG cells, there was a nearly 50% decrease in CD97 mRNA levels at this time point, whereas in GBM-6, there was a nearly 80% decrease. In U1242-MG cells, there was a less remarkable knockdown (20% decrease compared with the control cells), which was nevertheless statistically significant. When plated on Matrigel-coated filters of Transwell plates, we found that these decreases in CD97 mRNA levels were associated with significantly lower cellular invasiveness capacities (Fig. 5D ). In U251-MG cells treated with siRNA against CD97, the cellular invasiveness potential was decreased to roughly 53.85% of that of the control counterparts. In U1242-MG cells, even a modest decrease in CD97 RNA levels was associated with a striking decrease in invasiveness (25.5% of control), whereas in GBM-6 cells, the 80% decrease in CD97 mRNA levels caused a nearly 50% decrease in invasive capacity. Thus, it is clear that the expression of CD97 is functionally significant in glioma cells. We also examined the effects on cellular proliferation (if any) of knocking down CD97, even though such a role has not frequently been attributed to this molecule. Our findings showed that there were no significant differences between the proliferative rates of the control versus experimental groups across all the 3 cell lines (data not shown).
Discussion
We have identified, using gene expression profiling, genes whose expression levels correlate directly or inversely with WT1 levels in the specific context of malignant gliomas. Of the 27 genes whose expression patterns were positively correlated with that of WT1 (that is, downregulated with suppression of WT1 expression), 9 candidates were selected for having established or putative oncogenic functions, based on published literature. Conversely, of the 11 genes whose levels were inversely correlated (upregulated with WT1 silencing), 7 have been implicated in the suppression of tumorigenesis. We have validated the microarray findings for these genes in U251-MG cells with qRT-PCR and have also confirmed these expression patterns in 2 other GBM cell lines. Our promoter studies revealed potential binding sites for WT1 in the promoter regions of all but one of the putative target genes. In the lone exception-PDGF-D-the promoter region did, however, show potential binding sites for the Egr-1 family of transcription factors. It has been established in previous studies 23, 35, 45 that WT1 shares the consensus binding sequences recognized and bound by the Egr-1 family of proteins.
CD97 was uniformly downregulated in all 3 cell lines with WT1 silencing and displayed sites on its promoter that could be theoretically bound by WT1. Moreover, CD97 is well established as a facilitator of tumor cell invasiveness in other malignancies. Given these considerations, we further examined the role of this protein in gliomas. This novel undertaking revealed that in glioma cells, as in gastrointestinal malignancies and the fibrosarcoma cell line HT-1080, 20 the CD97 receptor fosters cellular invasiveness, and decreasing its endogenous expression caused a significant and striking decrease in the ability of the cells to invade through Matrigel.
The complexity of the WT1 protein has long posed a formidable challenge to those who have ventured to study its varied functions. Because of its vastly differing roles in different cell types, categorizing this protein as a tumor suppressor or an oncoprotein is difficult. In certain cells like the progenitor cells of the kidney, WT1 facilitates their exit from the cell cycle with subsequent differentiation. 15 In the neural and vascular progenitor cells, however, it has the exact opposite effect-facilitating proliferation and preventing differentiation. 15 Hence, any conclusions about its role(s) must be made strictly in the context of the cell type examined. We selected the microarray technique to study differences in gene expression arising out of manipulating the levels of WT1 in glioma cells that expressed it endogenously. Moreover, silencing the endogenous expression of the protein to look for the resultant differences was a more appropriate model to ac- curately assess the possible functions of WT1 rather than overexpressing WT1 in a WT1 null cell line, due to the myriad variables (WT1 isoforms and concentration) associated with the latter technique.
Identifying the target genes via which WT1 might influence its role in the neoplastic transformation of glial cells was important for many reasons. First, as a regulator of transcriptional and posttranscriptional processes, WT1 has the ability to coordinate many of the key aspects of glioma biology-proliferation, invasiveness, and angiogenesis-by regulating the expression of the molecules that mediate these processes. Moreover, given the rapid progress that is being made in the field of immunologically targeting WT1, 2, 17, 32, 33 our findings help to fill in the missing links in understanding how it functions. Finally, knowing the identity of its molecular associates can help in devising therapeutic strategies that target one or more of these components. Since these components may belong to different intracellular signaling pathways, targeting them simultaneously could work synergistically to have even greater effects against malignant gliomas.
The identification of at least 9 candidate oncogenes that were suppressed and 7 putative tumor suppressors that were upregulated by WT1 silencing confirmed our hypothesis that in gliomas, WT1 has more of an oncogenic function. Our study has also revealed for the first time that CD97 is aberrantly overexpressed in GBM cells. This protein has well-documented roles in mediating tumor cell invasion and even angiogenesis 1, 43 in other malignant cell types. In various gastrointestinal malignancies, an increased expression of CD97 has been demonstrated at the invading front of the tumor. 14, 21 Likewise, we have shown here that in glial neoplastic cells, also, it has a significant role in conferring invasiveness upon the cells. From our findings, it appears that in U1242-MG cells, the extent to which WT1 decreases cellular invasiveness roughly equals that seen with silencing of CD97 expression. In U251-MG and GBM-6 cells, on the other hand, WT1 silencing causes a much more pronounced decrease in cellular invasiveness than that seen with CD97 silencing alone. In both of these cell lines, expression of PDGF-D was also seen to be significantly decreased with lowered expression of WT1. It is well established that PDGF-D is a strong mitogenic and chemoattractant molecule that can initiate several malignant features, such as proliferation, invasion, and angiogenesis in brain tumors (reviewed by Wang et al. 44 ). A more detailed examination of the relationship of this growth factor to WT1 undoubtedly merits further attention.
We restricted the scope of this study to examining the expression and function of CD97 in glioma cell lines to establish well-characterized in vitro model systems that will allow continuing investigation of the molecular mechanisms involved with WT1 overexpression and the and a 6-to 21-fold increase in expression in the GBM cell lines investigated. C: Using siRNA directed against CD97, we confirmed a significant knockdown in CD97 RNA in the tumor cells on Day 4 posttransfection by qRT-PCR in U251-MG, U1242-MG, and GBM-6 cells. D: Treatment of U251-MG, U1242-MG, and GBM-6 cells with siRNA against CD97 resulted in a significant decrease in their ability to invade through the Matrigel-coated filters of transwell plates compared with cells that were treated with nontargeting siRNA. Cell invasiveness in CD97-silenced cells was expressed by using the CellTiter-Glo assay to first quantify the number of cells that had invaded through the Matrigel in the si groups versus scr groups and then expressing this value as a percentage of that seen in control (scr) cells. Three independent cultures of U251-MG, GBM-6, and U1242-MG cells were transfected with corresponding controls. *p < 0.05. correlated CD97 expression. Further, we chose to compare CD97 expression in these cells to that in normal human astrocytes as there was very little data describing expression of this proinvasive receptor molecule in the normal brain tissue components. Clearly, evaluation of CD97 expression in vivo, both in animal models and in human tumor samples, will also be needed. Along these lines, we can confirm that preliminary data from studies conducted by our laboratory have revealed CD97 mRNA expression by a high proportion of individual human glioma samples (data not shown). The detection of significantly higher levels of CD97 in the GBM cell lines and tumor specimens than is found in normal brain glia argues for a pathogenic role for this protein. Our results lay the groundwork for further analyses of the functional significance of CD97 using more sophisticated experimental techniques, such as brain slice invasion assays or in vivo studies.
We chose to downregulate CD97 expression as a more appropriate method in the initial evaluation of its inherent functional role. Future studies will seek to first identify the exact isoform(s) of CD97 (containing 3, 4, or 5 EGF repeats) that is (are) expressed in glioma cells. Upregulation of the identified isoform(s) in these cells can then be performed to confirm an increase in cellular invasiveness. Finally, although our promoter studies suggest putative binding sites for WT1 on the CD97 promoter, definitive evidence is still required to demonstrate WT1mediated transactivation of CD97 expression.
The ability to localize and therapeutically target the invading neoplastic cells in situ has for a long time been a challenge in the treatment of brain tumors. With the identification of CD97 expression and function in glioma cells, determining its ability to serve as a reliable marker of invasiveness using immunohistochemical staining of glioma tumor specimens opens up a potentially interesting line of investigation. Another option may be to devise a therapeutic strategy aimed at targeting the CD97 receptor, which could be relatively safe, since it is virtually absent in normal human astrocytes and the glia of normal brain (data not shown). Further investigations are also necessary to determine the effect of targeting the CD97 receptor on angiogenesis, as it is also known to affect this process.
Conclusions
Our studies emphasize the importance of WT1 in promoting GBM cellular invasiveness and reveal the identities of its putative target genes in glioma cells. We also show, for the first time in glioma cells, the expression and proinvasive function of CD97. Our study thus opens important new avenues in the field of glioma biology. More in-depth analyses of these molecules should carry us further in our attempts to find novel and more effective therapeutic targets for the treatment of GBM.
